II
ZNTL icon

Inspire Investing’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Inspire Investing’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50 Buy
21
+5
+31% +$13 ﹤0.01% 1074
2025
Q4 		$22 Buy
+16
New +$23 ﹤0.01% 1102

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Inspire Investing's ZNTL Position: Q1 2026 in Review

Inspire Investing increased its Zentalis Pharmaceuticals (ZNTL) stake by 31% in Q1 2026, buying an estimated $13 and bringing the position to 21 shares worth $50. The position accounts for ﹤0.01% of the portfolio, ranked #1074.

Inspire Investing first reported a position in ZNTL in Q4 2025 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Inspire Investing held 21 shares of Zentalis Pharmaceuticals worth $50 as of Q1 2026.
  • Inspire Investing bought 5 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $13.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Inspire Investing's portfolio in Q1 2026, its #1074 holding.
  • Inspire Investing first reported a position in Zentalis Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Inspire Investing's 13F filing for Q1 2026, filed 23 Apr 2026.